Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance

BACKGROUND: Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic resistance or develop acquired resistance. Here, we evaluated the mechanisms underlying acquired resistance to PDX and...

Descripción completa

Detalles Bibliográficos
Autores principales: Oiwa, Kana, Hosono, Naoko, Nishi, Rie, Scotto, Luigi, O’Connor, Owen A., Yamauchi, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325835/
https://www.ncbi.nlm.nih.gov/pubmed/34332580
http://dx.doi.org/10.1186/s12885-021-08607-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325835/
https://www.ncbi.nlm.nih.gov/pubmed/34332580
http://dx.doi.org/10.1186/s12885-021-08607-9

Ejemplares similares